Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

26 November 2020
Pharma

Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios.

Are you curious to know Why Precision Cancer Diagnostics Test Markets is growing and how it could benefit you?
Advanced diagnostics for cancer represent a major market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for non-invasive, diagnostic assays that can detect cancers earlier, molecularly subtype tumours to guide therapy decisions and monitor cancer recurrence in treated individuals. According to Visiongain analysis, the global precision cancer diagnostic test market is estimated to be valued at US$xx million in 2020 and is projected to reach at a market value of US$xx million by 2031.

Are significant new product launches propelling the market growth?
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers. New molecular diagnostics can simplify decision-making and reduce uncertainty, but can also complicate treatment selection: multiple tests may be used to identify markers, and their results are likely to vary in specificity and sensitivity. Molecular diagnostics are rapidly transforming drug development and patient selection.

Buy this report to find answers for below questions and how can help you to stay updated
• How much will the precision cancer diagnostic tests industry share grow during the forecast timeline?
• Are Political influence and online misinformation threatening cancer programmes worldwide?
• Is it true that public trust volatile and varying widely between countries?
• How scepticism about the safety of cancer diagnostic test tend to hamper precision cancer diagnostic test Sales Growth?
• Perceptions about cancer diagnostic test are much more volatile than they used to be?
• Are governments Planning to be extra vigilant about assessing public trust in cancer diagnostic test and responding rapidly to concerns?
• Consumers are more keen on thoroughness, effectiveness and safety of precision cancer diagnostic tests than other factors
• How are precision cancer diagnostic tests at diagnostic centres better than that done at hospitals?

Leading Players Profiled in the Report
Abbott Laboratories
Agilent Technologies, Inc.
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories, Inc.
Canon Inc.
Biocept, Inc.
Danaher Corporation (Danaher)
Roche Holding AG (Roche)
ANGLE plc
Epigenomics AG
General Electric Company
Siemens AG
Biomerieux SA
Hologic, Inc.
Myriad Genetics, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever